1. Introduction {#s0005}
===============

Mefloquine is a 4-quinolinemethanol antimalarial and antiparasitic drug that is structurally related to quinine. Although increasingly investigated for its promising antischistosomal properties ([@b0270; @b0045]), mefloquine is associated with a diverse range of adverse neurological effects ([@b0125]) which, together with the drug's neuropsychiatric contraindications ([@b0710]), have limited the drug's utility for its original antimalarial indications, particularly for prevention of disease ([@b0030; @b0070]).

According to recent European product labeling ([@b0190]) and the results of a randomized blinded trial ([@b0445]), commonly reported neurological effects from mefloquine which occur in 1--10% of prophylactic users include vertigo and visual difficulties. Additional idiosyncratic neurological effects reported in both European and U.S. product labeling include balance disorder, peripheral neuropathy, paresthesias, tremor, and ataxia ([@b0195; @b0200; @b0500]). Case reports also describe dysesthesias ([@b0205; @b0255]), disequilibrium ([@b0450]), nystagmus ([@b0410]), and photophobia ([@b0095]).

Although adverse neurological effects had previously been considered fully reversible ([@b0025]), diminishing in intensity with the slow elimination of the drug ([@b0425]), in 2012, the U.S. Food and Drug Administration (FDA) announced it was reevaluating mefloquine specifically for concerns of an association with lasting vestibular disorder based on new signals detected from its FDA Adverse Event Reporting System (FAERS) ([@b0680]). In 2013, European regulators updated the drug's core safety profile to warn that symptoms of polyneuropathy developing during mefloquine use were associated with risk of an irreversible neurological condition ([@b0090]), and FDA updated the U.S. product labeling with a boxed warning that other neurological effects including vertigo and loss of balance could be permanent in some cases ([@b0030; @b0375]).

Originally developed by the U.S. military and first licensed in Europe over a quarter century ago by F. Hoffmann-La Roche as Lariam® ([@b0125]), the innovator product was recently withdrawn from the U.S. market without explanation ([@b0630]). Generic formulations of mefloquine remain recommended in the U.S. ([@b0105]), but are decreasingly prescribed for the drug's original antimalarial indications ([@b0275; @b0310]). Similarly, while the innovator product remains licensed in many European countries ([@b0025]), certain authorities now recommend its use only as a drug of last resort ([@b0030; @b0070]).

Although the adverse neurological effects of mefloquine have been known for nearly a quarter century ([@b0720]), the recent emphasis by regulatory authorities of the permanent nature of some of these effects challenges the conventional belief that they are due merely to the long half-life of the drug ([@b0535]) and its continued presence in the body. The possibility of permanent neurological sequelae from the use of mefloquine introduces important new considerations for the continued rational use of the drug and calls for an improved effort to better characterize the pathophysiology of these effects.

In this opinion, it is proposed that many of the lasting adverse neurological effects of mefloquine are consistent with the chronic sequelae of a well characterized but idiosyncratic central nervous system (CNS) toxicity syndrome (or toxidrome) common to a number of historical antimalarial and antiparasitic quinolines and associated with a risk of permanent neuronal degeneration within specific CNS regions including the brainstem. Issues in the development and licensing of mefloquine are then considered in the context of historical awareness of the CNS toxicity of related quinoline drugs.

It is anticipated that the information presented in this opinion will aid in the future clinical recognition of the mefloquine toxidrome and its chronic sequelae, and in informing improved regulatory evaluation of mefloquine and related quinoline compounds, particularly as these drugs are investigated for expanded use worldwide for antiparasitic and other indications.

2. Historical evidence of quinoline CNS toxicity {#s0010}
================================================

Although not well described in the contemporary literature, the neurological toxidrome observed with mefloquine appears not to be unique to the drug, but instead shares a number of clinical characteristics in common with idiosyncratic CNS toxicity syndromes produced by certain related quinoline derivatives, including drugs that had historically been widely employed as antimalarials and antiparasitics.

While the naturally occurring cinchona alkaloid quinolines were historically well known to cause seemingly reversible neurological effects including symptoms of cinchonism ([@b0650]), the potential for lasting neurological effects from quinoline drugs was recognized in the mid 1940s, when certain synthetic quinoline antimalarials were found to cause irreversible CNS toxicity. In particular, the synthetic 8-aminoquinolines pamaquine and plasmocid, then both in common use as antimalarials ([@b0350; @b0055]), were linked to an idiosyncratic neurological syndrome accompanied by direct histopathological evidence of CNS neuronal degeneration in human and animal subjects. These drugs induced in the most extreme cases "highly localized degenerative changes in the (CNS) associated with functional derangement" ([@b0615]). Nearly three decades later the synthetic hydroxyquinoline clioquinol, then in common use as an antiparasitic ([@b0295]), had also been linked to a related idiosyncratic neurological syndrome again accompanied by histopathological evidence of CNS neuronal degeneration ([@b0605; @b0300]).

In the following sections, the clinical manifestations and histopathological findings associated with idiosyncratic intoxication with these three drugs are reviewed. Although comparable effects have been observed with a large number of other synthetic quinoline derivatives ([@b0560; @b0585]), the well-characterized and fairly conserved nature of the extensive CNS neuronal degeneration caused by these three drugs, together with their widespread historical use in antimalarial and antiparasitic therapy, are of greatest relevance in demonstrating the potential for lasting but previously unrecognized neurological effects from mefloquine.

2.1. Pamaquine {#s0015}
--------------

Pamaquine, known chemically as 8-(4-diethylamino-1-methylbutylamlno)-6-methoxyquinoline, originally developed by the Germans ([@b0085; @b0655]) and also known as praequine, plasmochin, or plasmoquine, was initially thought to be free of cinchona-like neurological effects. In use as an antimalarial since the late 1920s ([@b0230]), a large review of 258 cases of toxic reactions to the drug failed to identify any symptoms suggestive of CNS toxicity ([@b0230]). However, pamaquine was found in some users to induce similar symptoms of vertigo and photophobia ([@b0675; @b0230]) and visual disturbance ([@b0700]) to those commonly attributed to the cinchona alkaloids. Benign perceptions of the safety of pamaquine were challenged when a fatal case of human overdose, marked by blurred vision and facial paresthesias, was found at autopsy to have significant neuronal degeneration within specific brain structures including the brainstem. Careful histopathological study revealed extensive focal degeneration of the pontine nuclei, with mild to moderate degeneration of the vestibular nuclei, particularly the medial vestibular nuclei, as well as the nuclei of cranial nerves III, IV, and VI ([@b0330]).

Although comparable neurological reactions to pamaquine observed in rhesus monkeys had been characterized as reversible ([@b0565]), on histopathological testing, the drug in small doses was found to produce strikingly similar effects to those observed later in man ([@b0330]), causing swelling and subtle degeneration in scattered neurons throughout various brainstem nuclei including within the vestibular, supraspinal, ruber, ambiguus, dorsal motor, lateral cuneate, and lateral reticular nuclei, as well as those of cranial nerves III, IV, and VI ([@b0540]). At higher doses, the drug produced more extensive degeneration in these areas ([@b0540; @b0560]).

2.2. Plasmocid {#s0020}
--------------

The related 8-aminoquinoline plasmocid, known chemically as 8-(3-diethylaminopropylamino)-6-methoxyquinoline, originally developed by the Russians ([@b0215]) and also known as rhodoquine or Fourneau 710 ([@b0220]) was also found in early human use to cause cinchona-like neurological effects including vertigo, paresis and diplopia ([@b0140]). A 1945 review of the foreign literature cited a diverse range of more serious neurological effects including severe ataxia, convergence disorder, smoothing of the nasolabial fold, and deviation of the tongue ([@b0080]) suggestive of focal brainstem dysfunction. A review of 76 human cases of neurological effects attributed to plasmocid toxicity found a range of lasting deficits, including in equilibrium, coordination, and eye muscle movement; some of these symptoms "persisted for months or years after termination of treatment" ([@b0555]).

In the absence of published neurohistopathological testing of fatal human cases of plasmocid intoxication, early neurological effects were commonly attributed to cerebellar ataxia, polyneuritis, and optic atrophy ([@b0220]). However, histopathological testing in rhesus monkeys following administration of high doses of plasmocid revealed almost complete destruction of the nuclei of cranial nerves III, IV, and VI and of the vestibular nuclei; further administration produced variable patterns of injury extending into other brainstem nuclei ([@b0545; @b0335]), with highly scattered lesions extending throughout the medulla, pons, striatum, and limbic system ([@b0550; @b0610]). Authors speculated that "the effect of plasmocid on the human brain would be quite similar" to that observed in monkey ([@b0610]), and that multiple human cases of CNS toxicity were "doubtless similar to these in origin" ([@b0585]).

2.3. Clioquinol {#s0025}
---------------

By the early 1970s, accumulating evidence with the antiparasitic hydroxyquinoline clioquinol, known chemically as 5-chloro-7-iodo-8-quinolinol, had demonstrated a similar propensity for CNS toxicity to that observed with antimalarial 8-aminoquinolines. Although idiosyncratic cases of human toxicity, labeled subacute myelo-optic neuropathy (SMON) ([@b0295]) are characteristically associated with symptoms attributable to peripheral neurotoxicity, cases of SMON have also featured disequilibrium ([@b0210]), visual disturbances ([@b0265]), paresthesias and gait disturbances ([@b0670]), and vertigo and nystagmus ([@b0730]) equally attributable to CNS causes.

Although the neurohistopathology of SMON has been more typically characterized by extensive degeneration within the dorsal columns and the optic nerve, extensive evaluation of autopsy cases has also revealed degeneration of brainstem structures including the inferior olive and nucleus ruber ([@b0300]); the roots of cranial nerves V, VIII, and X ([@b0605]); and the nucleus gracilis ([@b0485]). On histopathological study across animal models, the drug produces scattered and highly variable degenerative lesions including within the distal optic nerve and dorsal funiculus of the spinal cord ([@b0250]) and fasciculus gracilis ([@b0640]) in beagle dogs; the optic tract and fasciculus gracilis in cats ([@b0645]); and the nucleus gracilis in rats ([@b0020]).

3. Evidence of mefloquine CNS toxicity {#s0030}
======================================

The most prominent neuropsychiatric effects identified during the development of mefloquine including vertigo initially resembled those of cinchonism induced by quinine ([@b0625; @b0725]). Presumably due to lack of direct histopathological evidence of quinine neurotoxicity and the presumed transient nature of neurological effects from drugs of the 4-quinolinemethanol class ([@b0575; @b0580]), the drug appears to have been assumed free of the known permanent CNS toxicity of pamaquine, plasmocid, and clioquinol.

The neurotoxicity of mefloquine was only first reported in papers published more than three decades after the drug's reported synthesis ([@b0435]), following experiments in cultured rat neuroblastoma and embryonic rat neuron cell lines ([@b0155]) over a range of neurophysiologically plausible concentrations ([@b0160]). In subsequent years, confirmatory evidence of the drug's neurotoxicity was also obtained ([@b0170; @b0165; @b0100]).

In direct histopathological testing in a rat model, high dose mefloquine induced neuronal degeneration evocative of the effects of clioquinol in the nucleus gracilis, nucleus cuneatus, and solitary tract ([@b0175]), and was accompanied by "anxiousness/hyperactivity" and functional changes in motor activity ([@b0175]). Study authors noted that the brainstem injury induced by mefloquine was "permanent in nature" ([@b0175]). Independent authors subsequently demonstrated mefloquine neurotoxicity in rat cortical neurons ([@b0245; @b0380]) and in human neuronal cell lines ([@b9005]; [@b0600]). While recommended confirmatory human neurohistopathological testing has yet to be performed ([@b0400]), clinical observations following intoxication from mefloquine at prophylactic doses have demonstrated lasting deficits consistent with brainstem lesions or dysfunction in the vicinity of the oculomotor and vestibular nuclei ([@b0410]).

While a variety of pathological mechanisms may be evoked to explain many of the signs and symptoms associated with mefloquine use, CNS neuronal degeneration similar to that observed in the animal model and similar to that caused by pamaquine and clioquinol in humans provides a highly parsimonious theoretical explanation for many of the drug's reported chronic neurological effects, including lasting cases of vertigo ([@b0225]), disequilibrium ([@b0410]), and paresthesias ([@b0325]).

For example, although mefloquine is a known peripheral ototoxicant ([@b0735; @b0145]), focal neuronal degeneration in the vicinity of the oculomotor and vestibular nuclei ([@b0410]), as observed at human autopsy with pamaquine and in animal models from plasmocid, provides a parsimonious pathophysiological explanation for at least some of the reported chronic vestibular effects of mefloquine. Similarly, while symptoms of mefloquine neuropathy have frequently been attributed to peripheral causes ([@b0690; @b0255]) including to C-fiber irritation ([@b0110]), the lack of direct evidence of specific peripheral neurotoxicity, together with the drug's demonstrated degenerative effects in the animal model in areas of the brainstem involved in the processing of sensory inputs including the nucleus gracilis, cuneatus and solitary tract ([@b0175]) suggest that CNS toxicity, analogous to that observed historically with clioquinol, may provide a more plausible and parsimonious pathophysiological explanation for these symptoms.

In spite of the large and growing body of neurotoxicity data from *in vivo* and *in vitro* studies, broader acceptance of the possibility of clinically significant CNS neurotoxicity from mefloquine has remained strangely elusive in the literature, possibly owing to the absence of published human neurohistopathology studies ([@b0400]). Interestingly, in the absence of comparable human neurohistopathology, and on the basis of animal studies alone, clinically significant human CNS neurotoxicity from plasmocid was never seriously contested and was even deemed "doubtless" by leading historical authorities ([@b0610; @b0585]). In contrast, some contemporary authors have appeared less inclined to acknowledge the possibility of similar effects from mefloquine, particularly at the relatively low doses encountered during prophylactic use, claiming that extrapolation of high dose neurotoxicity data from animal studies to human cases still requires the "bridging of a large knowledge gap" ([@b0535]).

Fortunately, human neuropharmacokinetic data is available that may effectively bridge this gap. For example, human autopsies have demonstrated mefloquine CNS accumulation at prophylactic dosing rates ([@b0260; @b0115]) to concentrations comparable to those after treatment ([@b0455]) and well beyond *in vitro* human cell line neurotoxicity thresholds ([@b9005]; [@b0600]). Additional *in vivo* ([@b0040]) and pharmacogenetic studies ([@b0005]) provide further neuropharmacokinetic insights into known CNS drug transport ([@b0460]) and metabolism ([@b9000]) pathways that may plausibly mediate idiosyncratic accumulation in CNS to neurotoxic concentrations during routine use.

Despite both toxicological and pharmacokinetic plausibility, demonstrating incontestable evidence of mefloquine CNS toxicity in individual clinical cases remains challenging. With use of mefloquine at higher doses for treatment of malaria, the possible confounding of signs and symptoms of CNS toxicity by those of comorbid cerebral malaria ([@b0695]) creates challenges for their attribution uniquely to the drug. Similarly, with use of mefloquine at lower prophylactic doses, a lack of sensitive prospective ascertainment, particularly in resource-constrained settings, may result in neurological effects not being identified ([@b0495]). Even when such effects are identified, demonstrating incontestable evidence of CNS toxicity may be made challenging by the microscopic and highly focal nature of most expected neuronal degeneration ([@b0175]), which as with presumed cases of clioquinol CNS toxicity ([@b0280]), would be frequently undetectable by conventional neuroimaging. Despite these limitations, reports of highly specific clinical findings, including central vestibulopathy ([@b0410]) occurring among those without any history of malaria or other plausible neurological etiologies establishes mefloquine CNS toxicity as a probable pathophysiological entity worthy of significant further investigation, particularly as the drug is considered for expanded use against parasitic disease and for other indications.

4. Mefloquine CNS toxicity in historical context {#s0035}
================================================

The long delayed recognition of the possibility of clinically significant CNS toxicity from mefloquine calls for an examination of the historical context of the drug's development and licensing as an antimalarial. Although the first synthesis of mefloquine, known chemically as 2,8-bis(trifluoromethyl)-(2-piperidyl)-4-quinolinemethanol, was reported in 1969 ([@b0435]), the drug was very closely related to the synthetic 4-quinolinemethanol compound 4-quinolyl-α-piperidylcarbinol first reported over three decades earlier in 1938 ([@b0010]). Mefloquine differs from this previously synthesized compound (later known as SN 2549) ([@b0060]) solely by addition of two trifluromethyl groups (CF~3~) at the 2 and 8 positions of the quinoline nucleus.

During early human testing of the 4-quinolinemethanols during the U.S. military's World War II era drug discovery program ([@b0015]) these drugs exhibited some evidence of the CNS toxicity observed from related synthetic quinoline compounds ([@b0560]), including producing visual photosensitivity or photophobia ([@b0465]). One particularly efficacious 4-quinolinemethanol known as SN 10,275 induced headache and visual photosensitivity ([@b0465]) but also induced phototoxicity which may have masked recognition of underlying CNS effects. Presumably owing to concerns of phototoxicity ([@b0505; @b0715]), investigation of 4-quinolinemethanols as antimalarials was formally abandoned in favor of the more promising 4-aminoquinolines ([@b0575]).

However, by the early 1960s ([@b0660]), owing ostensibly to concerns of rising resistance to the 4-aminoquinoline chloroquine, the U.S. military had initiated a new large scale drug discovery program ([@b0390]), during which time hundreds of thousands of compounds were evaluated for their antimalarial activity. Over 300 4-quinolinemethanols were evaluated in this effort, including some that had been previously tested during the earlier wartime program ([@b0575]). Mefloquine (initially known as WR 142,490) quickly emerged as the favored of these drugs based the results of limited human testing in prisoners ([@b0490; @b0665]) that suggested the drug was free of serious side effects. Soon after its first reported synthesis, mefloquine had been singled out by the U.S. military for larger-scale synthesis ([@b0435]) and commercialization by F. Hoffmann-La Roche ([@b0365]). So rapid was the testing of the drug in field settings that one researcher noted "Phase II clinical trials threatened to outstrip needed Phase I testing" ([@b0475]).

When the experimental 4-quinolinemethanol compounds WR-184,806 and WR-226,253 were noted in the early 1970s to evoke lightheadedness and difficulties in focusing ([@b0580]), these symptoms appear not to have been taken as evidence of possible CNS toxicity of the 4-quinolinemethanol class. Similarly, during testing of mefloquine, early and frequent reports of vertigo ([@b0235; @b0075]), "dizziness" ([@b0665; @b0235; @b0480]), and rare but sentinel reports of formication ([@b0235]), psychosis ([@b0235; @b0075]), confusion ([@b0240; @b0430; @b0065; @b0075]), amnesia ([@b0305]), and gait disturbance ([@b0235]) were seemingly also not considered in the context of earlier publications as evidence of potentially permanent CNS toxicity ([@b0575]). Importantly, and in marked contrast to the extensive testing conducted during earlier wartime drug development efforts ([@b0570]), no significant histopathological testing appears to have been undertaken prior to the U.S. licensure of mefloquine to rule out the drug's potential neurotoxicity.

Despite the lack of specific neurohistopathological testing, there nonetheless appears to have been clear awareness of the drug's potentially serious CNS effects. The original 1989 U.S. product insert acknowledged a risk of "disturbed sense of balance", and "visual disturbances", and cautioned that during prophylactic use, "if signs of unexplained anxiety, depression, restlessness or confusion are noticed, these may be considered prodromal to *a more serious event*" (emphasis added). Although this critical phrase was left undefined, the product insert warned of a risk of CNS disturbances including "encephalopathy of unknown etiology" during prophylactic administration ([@b0185]). In subsequent years, absent empiric understanding of the molecular basis of mefloquine's CNS effects, multiple authors posited imaginative but ultimately untested theories to explain the drug's marked neuropsychiatric toxicity ([@b0120; @b0400; @b0370]).

Although evidence suggestive of the neurotoxicity of mefloquine was published in 1996 ([@b0315]), it was only in 2003, 14 years after the drug's U.S. licensure, that the first results of neurotoxicity testing in rats were published by U.S. military affiliated researchers ([@b0160]). Recent attempts to mitigate mefloquine neurotoxicity, including efforts sponsored by the U.S. military to develop a human "safety test" ([@b0685]) to identify individuals with idiosyncratic susceptibility, have thus far failed to yield satisfactory results. Notwithstanding recent confusion over the absolute configuration of the currently marketed drug ([@b0150; @b0590]), randomized trials of enantiomeric mefloquine ([@b0290]), originally thought less likely to induce CNS effects owing to slightly lower average brain accumulation ([@b0050; @b0180]), have also demonstrated a propensity similar to the currently licensed racemic mixture to induce idiosyncratic "centrally mediated" symptoms of "dizziness" and difficulties in concentration ([@b0635]).

With rising awareness of the drug's neurotoxicity, by 2009, the U.S. military had prohibited the widespread use of mefloquine for prophylaxis ([@b0385]), and had returned to a policy of first-line use of doxycycline ([@b0415]), the drug of choice prior to the U.S. licensing of mefloquine 20 years earlier ([@b0510]). In response to the FDA boxed warning, senior U.S. military officials recently emphasized that mefloquine should be used for prophylaxis only as a "drug of last resort" ([@b0705]), while elite U.S. military units prohibited such use of the drug outright ([@b0470]).

While never explicitly addressing the potential implications of permanent CNS toxicity from the drug, senior U.S. military medical authors have acknowledged that mefloquine's neuropsychiatric effects might "confound the diagnosis and management of posttraumatic stress disorder and traumatic brain injury" making "the continued routine use of mefloquine less desirable" ([@b0345]), and noting that "with the availability of better-tolerated drugs, there is no need to use mefloquine for treatment unless other options are unavailable" ([@b0340]).

The near complete withdrawal of mefloquine within the U.S. military both for prophylaxis and treatment clearly marks the demise of the drug for the military indications for which it was original developed ([@b0125]). Interestingly, in 1978, a leading authority involved in the development of mefloquine had noted that the drug "promises to be broadly useful" in the treatment and prophylaxis of malaria, but that "\[if\] this promise is not realized, it will doubtless not be for lack of antimalarial activity, but rather because of toxicological attributes not identified in the small-scale studies pursued to date" ([@b0575]). Two decades earlier, during testing of related 8-aminoquinoline antimalarials ([@b0570]), this same authority had presciently cautioned that since "...in doses well below the lethal level \[these drugs\] produced striking symptoms of \[CNS\] injury associated with severe lesions in the principal nuclei of the proprioceptive, visual-reflex, and vestibulo cerebellar pathways... their capacity to evoke reactions which might mask symptoms of low grade neuronal injury, plus the likelihood of their widespread use in malaria therapy, make a detailed search for CNS lesions highly desirable" ([@b0560]). With awareness of the potential for lasting CNS toxicity finally emerging over 40 years after mefloquine's initial development, it appears worthy of further investigation to determine precisely why such a "highly desirable" search was never performed, and why pre-licensure testing appears to have been limited only to "small-scale" studies.

5. Conclusions {#s0040}
==============

In this opinion, it has been argued that many of the idiosyncratic chronic neurological sequelae associated with mefloquine use not only have a solid biological basis, but are consistent with a more generalized CNS toxicity syndrome common to certain historical quinoline drugs and associated in both animal and human studies with a risk of neuronal degeneration particularly within specific brainstem nuclei. In the four decades since the development of mefloquine, and absent seeming awareness of its potential to induce permanent CNS toxicity, many of the drug's most severe idiosyncratic neuropsychiatric effects have been attributed by influential authors to the stresses of travel or to latent or pre-existing mental illness ([@b0320; @b0520; @b0525; @b0530]), or to "media hype" ([@b0515]). With the benefit of the insights presented in this opinion, these prior explanations for many of mefloquine's reported adverse effects now appear unsatisfactory.

The recent emphasis by regulatory authorities of the potential for permanent neurological effects from mefloquine, coming four decades too late to rationally inform most antimalarial use of the drug, underscores the need for sensitive prospective evaluation ([@b0495]) of neurological endpoints during clinical testing as the drug is repositioned for possible widespread antiparasitic use, including in the treatment of schistosomasis. However, given the clinically occult CNS toxicity that may result from use of mefloquine, the insights of this opinion also underscore the critical importance of better characterizing the molecular basis of quinoline neurotoxicity, and emphasize the need to ensure comparable neurohistopathological testing ([@b0560]) is performed in appropriate animal models prior to the future licensing of related quinoline drugs.

Such testing appears particularly needed for tafenoquine ([@b0395]), an 8-aminoquinoline initially developed by the U.S. military ([@b0285]) and related structurally both to pamaquine and plasmocid, and associated in pre-licensing trials with a similar risk of vertigo as mefloquine ([@b0395]). While tafenoquine has been eagerly anticipated for its utility against vivax malaria ([@b0035]) and potentially against leishmaniasis ([@b0355; @b0360]), the recent granting by the U.S. FDA of Breakthrough Therapy ([@b0595]) status, in the absence of any published neurohistopathological testing, risks recreating the sense of urgency that contributed to the approval of mefloquine in the absence of appropriate CNS safety data ([@b0125; @b0130]).

Lastly, although of incidental interest to the parasitology community, these insights also suggest the need for caution as mefloquine ([@b0405]) and other currently licensed antiparasitic and antimalarial quinoline drugs are increasingly evaluated for treatment of neuropsychiatric and neurologic conditions, including behavioral dyscontrol ([@b0135]), affective dysregulation ([@b0620]), chorea ([@b0440]), progressive multifocal leukoencephalopathy ([@b0115]), multiple sclerosis ([@b0420]), and glioblastoma ([@b9005]), which might plausibly mask or make difficult the recognition of CNS toxicity and low grade neuronal injury.

Disclaimer {#s0045}
==========
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